Sheryl brings a wealth of editorial experience to MJH Life Sciences’ Eye Care Network, having engaged with the readers and the greater ophthalmic community of Ophthalmology Times for more than 20 ...

Stephen Tsang, MD, PhD, reviews promising optogenetic therapy results for retinitis pigmentosa and Stargardt disease, enhancing vision and mobility for patients.

A panelist discusses how strategic eye selection and proactive patient counseling optimize success and satisfaction with NT-501 implantation for bilateral MacTel type 2. A panelist discusses how ...

A panelist discusses how careful timing, patient education, and bilateral treatment planning strengthen real-world NT-501 management for MacTel type 2. A panelist discusses how key takeaways from ...

A panelist discusses how evolving imaging and the approval of NT-501 therapy are transforming macular telangiectasia type 2 from a diagnostic challenge into a treatable condition. A panelist discusses ...

A panelist discusses how individualized imaging-based decisions guide when to initiate NT-501 therapy in both early and advanced stages of MacTel type 2. A panelist discusses how selecting the first ...

Sharon Fekrat, MD, FACS, FASRS, shares insights on the retinal manifestations of antipsychotic medications.

An expert summarizes real-world GA management lessons, highlighting personalized imaging-guided care and patient-centered strategies to maintain vision stability. Dr. Sambhara closes with ...

An expert outlines vision-preserving strategies for monocular high-risk GA, emphasizing early intervention and tailored therapy for safety and stability. Dr. Sambhara presents an 82-year-old monocular ...

A mutation-agnostic gene therapy approach offers new possibilities for patients, especially those with inherited retinal diseases. For decades, I had to deliver the difficult message to patients with ...

This acquisition will include Adverum’s lead candidate, Ixo-vec, a gene therapy treatment for wet AMD. According to the release, the terms of the 2 companies merger agreement include, Lilly will ...

Emerging anti-VEGF agents offer enhanced durability and anatomic outcomes in retinal disease. The structural differences among newer second-generation anti-VEGF agents—and their implications for ...